Literature DB >> 29843579

The CD40/CD40L system regulates rat cerebral microvasculature after focal ischemia/reperfusion via the mTOR/S6K signaling pathway.

Run-Hao Jiang1, Xiao-Quan Xu1, Chen-Jiang Wu1, Shan-Shan Lu1, Qing-Quan Zu1, Lin-Bo Zhao1, Sheng Liu1, Hai-Bin Shi1.   

Abstract

OBJECTIVE: The role of CD40/CD40 ligand (CD40L) in microvascular thrombosis is now widely accepted. However, the exact mechanisms linking the CD40/CD40L system and the soluble form of CD40L (sCD40L) with microvascular thrombosis are currently a topic of intensive research. The objective of this study was to assess the potential mechanisms in CD40/CD40L system-regulated microvascular thrombosis after focal ischemia/reperfusion (I/R).
METHODS: Rats were subjected to 60-min transient middle cerebral artery occlusion (MCAO). The experiments were divided into three groups: sham operation, MCAO, and MCAO + CD40 antagonist. Dynamic changes of serum-free sCD40L levels for 0, 1, 3, 5, 6, and 12 h by ELISA detecting kit after focal I/R were observed, and the CD40 expression levels in both platelet surface and vascular endothelial cell surface were measured by flow cytometry and immunofluorescence, respectively. Cerebral infarct volume was analyzed 12 h after reperfusion. mTOR/S6K signaling was determined by Western blot.
RESULTS: A comparison of thrombus formation between MCAO and CD40 antagonist treatment rats revealed a role for CD40 and/or CD40L in the inflammation-enhanced thrombosis responses in both of the platelet and vascular endothelial cell. MCAO rats yielded an acceleration of thrombus formation that was accompanied by increased CD40 levels in serum. The brain infarction was significantly decreased in CD40 antagonist treatment group compared to MCAO model group. The mTOR/S6K signaling was activated in MACO model than that of CD40 antagonist treatment group.
CONCLUSIONS: Our findings indicate that CD40/CD40L system contributes to microvascular thrombosis and brain infarction induced by MCAO and reperfusion. The mTOR/S6K signaling pathway is involved in the regulation of cerebral microvasculature after focal I/R by CD40/CD40L. ABBREVIATIONS: AKT: protein kinase B; CD40L: CD40 ligand; CSF: cerebrospinal fluid; FITC: fluorescein isothiocyanate; I/R: ischemia/reperfusion; MCAO: middle cerebral artery occlusion; mTOR: mechanistic target of rapamycin; PE: P-phycoerythrin; sCD40L: soluble form of CD40L; TNF-a: tumor necrosis factor-alpha; WT: wild type.

Entities:  

Keywords:  CD40/CD40L; Cerebral ischemia; cerebral microvasculature; mTOR/S6K; rat

Mesh:

Substances:

Year:  2018        PMID: 29843579     DOI: 10.1080/01616412.2018.1473075

Source DB:  PubMed          Journal:  Neurol Res        ISSN: 0161-6412            Impact factor:   2.448


  5 in total

1.  The mechanism by which enoxaparin sodium-high-viscosity bone cement reduces thrombosis by regulating CD40 expression in endothelial cells.

Authors:  Linchao Sang; Kangning Hao; Luobin Ding; Xiaoyu Shen; Hui Sun; Dehao Fu; Xiangbei Qi
Journal:  BMC Musculoskelet Disord       Date:  2022-05-30       Impact factor: 2.562

2.  Inhibition of IL-32 Expression Ameliorates Cerebral Ischemia-Reperfusion Injury via the NOD/MAPK/NF-κB Signaling Pathway.

Authors:  Chao Liu; Xiaohui Xu; Chao Huang; Dandan Shang; Li Zhang; Yupeng Wang
Journal:  J Mol Neurosci       Date:  2020-05-30       Impact factor: 3.444

Review 3.  Role of the Platelets and Nitric Oxide Biotransformation in Ischemic Stroke: A Translative Review from Bench to Bedside.

Authors:  Maciej Bladowski; Jakub Gawrys; Damian Gajecki; Ewa Szahidewicz-Krupska; Anna Sawicz-Bladowska; Adrian Doroszko
Journal:  Oxid Med Cell Longev       Date:  2020-08-28       Impact factor: 6.543

Review 4.  Influence of Cardiometabolic Risk Factors on Platelet Function.

Authors:  Cristina Barale; Isabella Russo
Journal:  Int J Mol Sci       Date:  2020-01-17       Impact factor: 5.923

5.  Astrocyte-Derived TNF-α-Activated Platelets Promote Cerebral Ischemia/Reperfusion Injury by Regulating the RIP1/RIP3/AKT Signaling Pathway.

Authors:  Wei Li; Dengping Liu; Jiaqi Xu; Jun Zha; Chen Wang; Jianzhong An; Zhanli Xie; Shigang Qiao
Journal:  Mol Neurobiol       Date:  2022-07-04       Impact factor: 5.682

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.